TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Hypertension Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Mild to moderate essential hypertension : sitting diastolic blood pressure measured at Placebo visit and Baseline are 90\~109mmHg inclusive and the difference between sitting diastolic blood pressures measured at Placebo visit and Baseline(Day0) is under 7mmHg.~* Subjects who agree to participate in this sudy and give written informed consent~* Subjects considered to understand the study, be cooperative, and able to be followed-up until the end of the study~Exclusion Criteria:~* The sitting DBP is less than 89mmHg or more than 110mmHg or severe hypertensive patient with sitting systolic blood pressure over 200mmHg Patients with secondary hypertension~* Patients with severe renal(Creatinine more 1.5 times than upper limit of normal), gastrointestinal, hematological or hepatic(AST, ALT more 2 twice more than upper limit of normal)disease etc. which might affect absorption, disposition, metabolism or excretion of the drug~* Patients with postural hypotension~* Patients with sever insulin dependent diabetes mellitus or uncontrolled diabetes mellitus(HbA1c\>9%, regimen change of oral hypoglycemic agents within 12weeks, treated insulin before screening)~* Patients with a history of myocardial infarction, severe coronary artery disease or clinically significant heart failure or valvular defect in last 6 months~* Patients with consumptive disease, autoimmune disease, connective tissue disease~* Patients with a history of type B or C hepatitis(include carrier)~* Patients with HIV or hepatitis~* Patients with clinically significant laboratory abnormality~* Patients receiving any drugs known to affect blood pressure or medical treatments that can influence the blood pressure~* Patients with allergy or contraindication to any angiotensin II receptor antagonists~* Female of childbearing potential who does not undergo hysterectomy or is not post-menopausal~* Patients judged to have a history of alcohol or drug abuse by the investigator~* Patients participated other clinical trial 12 weeks before Screening Patients judged to be inappropriate for this study by the investigator with other reasons

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 2 (Type: ACTIVE_COMPARATOR): Losartan group
- 1 (Type: ACTIVE_COMPARATOR): Fimasartan 60mg, 120mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Given written/signed informed consent~* Age 18 to 50 years old (inclusive) as of the date the informed consent form (ICF) was signed~* Diagnosis of MS per updated McDonald criteria, and cranial magnetic resonance imaging (MRI) scan demonstrating white matter lesions attributable to MS within 5 years of screening~* Onset of MS symptoms (as determined by a neurologist, either at screening or retrospectively) within 5 years of the date the ICF was signed~* Expanded Disability Status Scale (EDSS) score 0.0 to 3.0 (inclusive) at screening~* Greater than or equal to (\>=) 2 MS attacks (first episode or relapse) occurring in the 24 months prior to the date the ICF was signed, with \>=1 attack in the 12 months prior to the date the ICF was signed, with objective neurological signs confirmed by a physician, nurse practitioner, or other Genzyme-approved health-care provider and the objective signs could be identified retrospectively~Exclusion Criteria:~* Received prior therapy for MS other than corticosteroids, for example, alemtuzumab, interferons, intravenous immunoglobulin, glatiramer acetate, natalizumab, and mitoxantrone~* Exposure to azathioprine, cladribine, cyclophosphamide, cyclosporine A, methotrexate, or any other immunosuppressive agent other than systemic corticosteroid treatment~* Any progressive form of MS~* History of malignancy (except basal skin cell carcinoma)~* CD4 + , CD8 + count, B cell, or absolute neutrophil count less than (\<) lower limit of normal (LLN) at screening~* Known bleeding disorder (for example, dysfibrinogenemia, factor IX deficiency, hemophilia, Von Willebrand's disease, disseminated intravascular coagulation, fibrinogen deficiency, or clotting factor deficiency)~* Significant autoimmune disease including but not limited to immune cytopenias, rheumatoid arthritis, systemic lupus erythematosus, other connective tissue disorders, vasculitis, inflammatory bowel disease, severe psoriasis~* Presence of anti-thyroid stimulating hormone (TSH) receptor (TSHR) antibodies (that is, above the LLN)~* Active infection or at high risk for infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Alemtuzumab (Type: EXPERIMENTAL): None
- Interferon Beta-1a (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type 2 Diabetes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be at least 18 years of age,~* Must have an FEV1 of \> 70% of predicted,~* Must have evidence of bronchial hyperreactivity to methacholine as defined by a methacholine provocation causing a 20% or greater fall in FEV1 (PC20) \< 8 mg/ml~* Use of inhaled steroid is permitted; however, no change in inhaled steroid dosage will be permitted over the duration of study~* Must have a normal platelet count,~* Must be willing to and competent to sign the consent form~Exclusion Criteria:~* Subjects that do not have allergic asthma will be excluded.~* Subjects with ER visits or upper respiratory infections within the last six weeks will be excluded.~* Subjects with tobacco use within the past year or \> 10 pack year history of tobacco use will be excluded.~* Subjects with serum IgE levels of less than 30 or greater than 700 Iu/mL will be excluded.~* Subjects that require oral steroid use will be excluded.~* Subjects who weigh \< 30 kg or \> 150 kg are excluded, and subjects with baseline IgE levels greater than 300 may be excluded, depending on weight~* Pregnant or nursing females will be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* If female, cannot be of reproductive potential~* Treatment with an appropriate, stable dose of statin ± other lipid modifying therapy for at least 6 weeks and who is not at LDL-C goal per their category in the Japan Atherosclerosis Society guidelines~Exclusion Criteria:~* Previously participated in a study with a cholesteryl ester transfer protein (CETP) inhibitor~* Homozygous and heterozygous familial hypercholesterolemia~* Severe chronic heart failure~* Uncontrolled cardiac arrhythmias, myocardial infarction (MI), percutaneous coronary intervention (PCI), coronary artery by-pass graft (CABG), unstable angina, or stroke within 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Anacetrapib (Type: EXPERIMENTAL): Participants will receive 100-mg anacetrapib, orally, once-daily for 24 weeks. Participants will continue on once-daily 100-mg anacetrapib during 28 week open-label extension.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo tablet, orally, once daily for 24 weeks. Participants will be switched to once-daily 100-mg anacetrapib during 28 week open-label extension.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients at least 18 years of age~* CHC infection, genotype 1~* use of 2 forms of contraception during study in both men and women~Exclusion Criteria:~* previous systemic therapy with anti-viral, anti-neoplastic, or immunomodulatory agents~* medical condition associated with chronic liver disease (e.g., hemochromatosis, autoimmune hepatitis, metabolic liver disease, alcoholic liver disease, toxin exposure)~* decompensated liver disease~* women who are pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Peginterferon Alfa-2a + Ribavirin (Type: EXPERIMENTAL): Participants received Peginterferon alfa-2a (40 kD) \[Pegasys\] at a dosage of 180 microgram (μg), subcutaneously (SC), once a week plus Ribavirin \[Copegus\] 1000 or 1200 milligram (mg)/day), orally, \[according to body weight, lesser than or greater than/equal to (\< or \>/=) 75 kilogram (kg), respectively\] twice daily during the randomized treatment period for 12 weeks. Participants who completed the randomized treatment period of 12 weeks and wished to continue therapy were given Peginterferon alfa-2a 180 μg SC once weekly plus Ribavirin 1000 or 1200 mg/day orally (\< or \>/=75 kg body weight, respectively twice daily for an additional 36 weeks to complete a full 48-week treatment course. After treatment completion, participants were followed-up for safety for 24 weeks.
- Peginterferon Alfa-2b + Ribavirin (Type: ACTIVE_COMPARATOR): Participants received Peginterferon alfa-2b (12 kD) \[PEG-Intron\] at a dosage of 1.5 μg/kg SC once weekly plus Ribavirin \[Rebetol\] 1000 or 1200 mg/day orally (\< or \>/=75 kg body weight, respectively) twice daily during the randomized treatment period for 12 weeks. Participants who completed the randomized treatment period of 12 weeks and wished to continue therapy were given Peginterferon alfa-2a 180 μg SC once weekly plus Ribavirin 1000 or 1200 mg/day orally (\< or \>/=75 kg body weight, respectively) twice daily for an additional 36 weeks to complete a full 48-week treatment course. After treatment completion, participants were followed-up for safety for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Using Health-related Quality of Life (HRQL) in Routine Clinical Care

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* pre-lung transplant:subjects who are included on the waiting list and are being seen at the out-patient clinic~* post-lung transplant subjects.~Exclusion Criteria:~* younger than 18 years of age~* diagnosed as being cognitively impaired~* unable to complete questionnaires in English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Increased Renal Oxygenation and Angiotensin Converting Enzyme Inhibition

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* healthy female between 45 and 55 years~Exclusion Criteria~* man and~* health female below 45 and above 55 years

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Captopril 25mg (Type: OTHER): To study the renal blood oxygenation, the subjects took captopril (25mg).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Safety and Efficacy of Naltrexone and Scopolamine Utilized in the Treatment of Major Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male or female, aged 18-65~* in good health other than major depression for 8 weeks or more~* negative pregnancy test~* able to comply with instructions~* able to provide informed consent~Exclusion Criteria:~* pregnant or lactating~* danger to self or others~* severe kidney or liver disease~* schizophrenia~* allergy to scopolamine or naltrexone~* glaucoma~* Monoamine oxidase (MAO) inhibitor use

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- control (Type: PLACEBO_COMPARATOR): Participants will receive placebo medication
- Active (Type: EXPERIMENTAL): participants will receive active medications scopolamine and naltrexone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants who require continuous NSAID therapy during the treatment period with the study drug~2. Participants who have completed the preceding study~3. Outpatient (including inpatient for examinations)~Exclusion Criteria:~1. Participants deemed to be ineligible to participate in the study by the principal investigator or investigator due to the occurrence of adverse events in the preceding study~2. Participants who are scheduled to change the type and dosage regimen of NSAID~3. Participants with ulcers or bleeding in stomach or duodenum, endoscopically confirmed during the preceding study~4. Participants with small intestine bleeding, large intestine bleeding, or gastrointestinal bleeding of unknown etiology~5. Participants who have a history of surgery which affects gastric acid secretion (e.g., resection of upper gastrointestinal tract, vagotomy) or who are scheduled to undergo such surgery~6. Participants with a previous or current history of Zollinger-Ellison syndrome, or other gastric acid hypersecretion disorders~7. Participants with a previous or current history of aspirin-induced asthma

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TAK-438 10 mg QD (Type: EXPERIMENTAL): None
- TAK-438 20 mg QD (Type: EXPERIMENTAL): None
- Lansoprazole 15 mg QD (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combined Saphenous Nerve and IPACK Blocks Versus Infiltration Analgesia After Anterior Cruciate Ligament Reconstruction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Statut ASA I-III.~* Patient scheduled for anterior crutiate ligament reconstruction under general anesthesia.~Exclusion Criteria:~* Pregnancy.~* Contraindication to local anesthesia.~* Patient with chronic pain, opioid consumption or alcohol consumption.~* Patient with coagulation trouble, hepatic dysfunction or renal dysfunction.~* Patient with diabetic or femoral neuropathy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IPACK block (Type: EXPERIMENTAL): Saphenous nerve block and IPACK block by anesthetist under ultrasound guidance.
- Local infiltration analgesia (Type: ACTIVE_COMPARATOR): Periarticular infiltration by surgeon

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Ambulatory adults aged 50 and older.~2. Medically stable, as determined by medical history and targeted physical examination. Medically stable is defined as no change in diagnoses or chronic medications (dose or class) for medical reasons in the 3 months prior to study.~3. Absence of underlying conditions that make participation in the study contrary to the subject's best interest.~4. Able to understand and comply with planned study procedures.~5. Provides written informed consent prior to initiation of any study procedure.~Exclusion Criteria:~1. Known contraindication to either study vaccine (see product package inserts)~2. Receipt of any other influenza vaccine within 180 days prior to enrollment in this study.~3. Underlying disease or ongoing therapy that might cause immunocompromise, e.g. cytotoxic agents or supraphysiologic doses of corticosteroids, such that response to vaccination might be sub-optimal.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Flublok Quadrivalent Influenza Vaccine (Type: EXPERIMENTAL): Intramuscular injection of vaccine containing 4 x 45µg (180µg total) of each recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and two lineages of influenza B viruses identified for the season in which the trial is conducted in a total volume of 0.5 mL
- Inactivated Influenza Vaccine (Type: ACTIVE_COMPARATOR): Intramuscular injection of vaccine contains 4 x 15µg (60µg total) of HA derived from the same influenza A/H1N1 and A/H3N2 and influenza B strains in a total volume of 0.5mL.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Interest of a Bi-truncal Nerve Block (Femoral + Sciatic) Extended, Systematically Associated With General Anesthesia, in the Femoropopliteal Bypass: Study of Post-operative Analgesia and Peripheral Circulation Downstream

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients to benefit a planned femoropopliteal bypass through PAOD stage II or III.~* Aged 18 to 80 years.~* Having given their consent.~* Affiliated with a social security scheme.~Exclusion Criteria:~* Patients with PAOD stage I or IV.~* Chronic respiratory failure.~* Severe coronary insufficiency.~* Renal or hepatic impairment.~* Patients with chronic pain or preoperative long-term opioid treatment.~* Patients with cognitive impairment (judged by the investigator) that may interfere with:~  * informed consent,~ * the collection of endpoints,~ * the use of patient-controlled analgesia.~* Severe abnormality of hemostasis (platelets \<80.000 / ml) and / or of coagulation (PT \<50%, factor V \<50%).~* Patients with diabetes mellitus and / or diabetic neuropathy.~* Pregnant or nursing women, women of childbearing age.~* Refusal of the protocol.~* Minor or major protected patients.~* Contraindications to one of the following products:~levobupivacaine, clonidine, morphine, paracetamol, nefopam.~- Patients with a contra-indication to the administration of sufentanil: hypersensitivity to any component, hypersensitivity to morphine, hypersensitivity to opiates.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- NaC1 (Type: OTHER): The aim of this study is to assess, in patients scheduled for femoropopliteal bypass, the benefit of a double peripheral nerve block (femoral + sciatic) with levobupivacaine and clonidine in a single dose, performed before induction of general anaesthesia, on analgesia postoperatively assessed by morphine consumption.
- Levobupivacaine + clonidine (Type: OTHER): The aim of this study is to assess, in patients scheduled for femoropopliteal bypass, the benefit of a double peripheral nerve block (femoral + sciatic) with levobupivacaine and clonidine in a single dose, performed before induction of general anaesthesia, on analgesia postoperatively assessed by morphine consumption.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete